{
  "trial_id": "NCT01805882",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Eighteen years of age or older at screening.",
      "label": "met"
    },
    {
      "criterion": "Female study participants with childbearing potential (as defined below) and all males must be willing to practice either: Abstinence from sexual intercourse or One or more forms of effective barrier contraception throughout dosing and for 30 days following the last dose. This cannot include hormonal contraception for female subjects.",
      "label": "met"
    },
    {
      "criterion": "Effective forms of barrier contraception include: a male condom with spermicide use by female sexual partner of a female condom with spermicide",
      "label": "unknown"
    },
    {
      "criterion": "Non-childbearing potential (i.e., physiologically incapable of becoming pregnant) includes any female who: Has had a hysterectomy or Has had a bilateral oophorectomy (ovariectomy) or Is post-menopausal (a demonstration of a total cessation of menses for greater than or equal to 1 year)",
      "label": "unknown"
    },
    {
      "criterion": "Has had a bilateral tubal ligation or fallopian tube inserts",
      "label": "unknown"
    },
    {
      "criterion": "Chronic HCV GT-1 or GT-4 infection as documented by greater than or equal to 1 measurement of serum HCV RNA greater than or equal to 2,000 international units per milliliter during screening and at least one of the following: A positive anti-HCV antibody, HCV RNA, or HCV genotype test result greater than or equal to 12 months prior to the baseline (day 0) visit together with current positive HCV RNA and anti-HCV antibody test results",
      "label": "met"
    },
    {
      "criterion": "A liver biopsy consistent with chronic HCV infection disease, such as the presence of fibrosis.",
      "label": "unknown"
    },
    {
      "criterion": "Group A may include up to 20% of subjects with compensated cirrhosis.",
      "label": "met"
    }
  ],
  "exclusion": [
    {
      "criterion": "Current or prior history of any of the following: Clinically-significant illness (other than HCV) or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol; subjects currently under evaluation for a potentially clinically-significant illness (other than HCV) are also excluded.",
      "label": "not_met"
    },
    {
      "criterion": "Gastrointestinal disorder or post operative condition that could interfere with the absorption of the study drug.",
      "label": "unknown"
    }
  ],
  "notes": "The patient is a 53-year-old man with chronic HCV infection for the past 2 years. He has been on IFN (100 mg/week) plus RBV (400 mg/day) combination therapy for the past 9 months and direct antiviral drugs were added to his treatment 6 months ago.",
  "_meta": {
    "topic_id": "27",
    "trial_id": "NCT01805882",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}